Organogenesis Holdings Inc.
ORGO
Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preservā¦ read more
Healthcare
Drug ManufacturersāSpecialty & Generic
9 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.79
Price+4.07%
$0.07
1Y
Price
Market Cap
$230.327m
Small
Price/Earnings 3y Avg5y Avg
59.7x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-150.7%
EBITDA Margin-150.8%
Net Profit Margin+48.3%
Free Cash Flow Margin-150.7%
EBITDA Margin-150.8%
Net Profit Margin+48.3%
Free Cash Flow MarginRevenue
$513.565m
-8.8%
1y CAGR+6.4%
3y CAGR+3.8%
5y CAGREarnings
-$284k
-100.8%
1y CAGR+1339.2%
3y CAGR+987.4%
5y CAGREPS
-$0.16
-206.7%
1y CAGR+422.8%
3y CAGR+300.4%
5y CAGRBook Value
$381.347m
$519.992m
Assets$138.645m
Liabilities$70.861m
DebtDebt to Assets
13.6%
1.9x
Debt to EBITDAFree Cash Flow
$17.082m
+169.8%
1y CAGR-184.0%
3y CAGR-94.9%
5y CAGRNo items found.
Press Releases
Statements and updates from the company